Literature DB >> 32087041

Angelman syndrome: a journey through the brain.

Carina Maranga1,2, Tiago G Fernandes1, Evguenia Bekman1,3,2, Simão Teixeira da Rocha2.   

Abstract

Angelman syndrome (AS) is an incurable neurodevelopmental disease caused by loss of function of the maternally inherited UBE3A gene. AS is characterized by a defined set of symptoms, namely severe developmental delay, speech impairment, uncontrolled laughter, and ataxia. Current understanding of the pathophysiology of AS relies mostly on studies using the murine model of the disease, although alternative models based on patient-derived stem cells are now emerging. Here, we summarize the literature of the last decade concerning the three major brain areas that have been the subject of study in the context of AS: hippocampus, cortex, and the cerebellum. Our comprehensive analysis highlights the major phenotypes ascribed to the different brain areas. Moreover, we also discuss the major drawbacks of current models and point out future directions for research in the context of AS, which will hopefully lead us to an effective treatment of this condition in humans.
© 2020 Federation of European Biochemical Societies.

Entities:  

Keywords:  zzm321990UBE3Azzm321990; Angelman syndrome; cerebellum; cortex; hippocampus

Year:  2020        PMID: 32087041     DOI: 10.1111/febs.15258

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  8 in total

1.  Motor Deficits Coupled to Cerebellar and Striatal Alterations in Ube3am-/p+ Mice Modelling Angelman Syndrome Are Attenuated by Adenosine A2A Receptor Blockade.

Authors:  Ana Moreira-de-Sá; Francisco Q Gonçalves; João P Lopes; Henrique B Silva; Ângelo R Tomé; Rodrigo A Cunha; Paula M Canas
Journal:  Mol Neurobiol       Date:  2021-01-19       Impact factor: 5.590

Review 2.  Ubiquitin and Ubiquitin-like Proteins in Cancer, Neurodegenerative Disorders, and Heart Diseases.

Authors:  Jin-Taek Hwang; Ahyoung Lee; Changwon Kho
Journal:  Int J Mol Sci       Date:  2022-05-02       Impact factor: 6.208

3.  Autism Symptoms in Children and Young Adults With Fragile X Syndrome, Angelman Syndrome, Tuberous Sclerosis Complex, and Neurofibromatosis Type 1: A Cross-Syndrome Comparison.

Authors:  Kyra Lubbers; Eefje M Stijl; Bram Dierckx; Doesjka A Hagenaar; Leontine W Ten Hoopen; Jeroen S Legerstee; Pieter F A de Nijs; André B Rietman; Kirstin Greaves-Lord; Manon H J Hillegers; Gwendolyn C Dieleman; Sabine E Mous
Journal:  Front Psychiatry       Date:  2022-05-16       Impact factor: 5.435

4.  A cross-species spatiotemporal proteomic analysis identifies UBE3A-dependent signaling pathways and targets.

Authors:  Nikhil J Pandya; Sonja Meier; Stefka Tyanova; Marco Terrigno; Congwei Wang; A Mattijs Punt; E J Mientjes; Audrey Vautheny; Ben Distel; Thomas Kremer; Ype Elgersma; Ravi Jagasia
Journal:  Mol Psychiatry       Date:  2022-03-09       Impact factor: 13.437

5.  Imprinting fidelity in mouse iPSCs depends on sex of donor cell and medium formulation.

Authors:  Maria Arez; Melanie Eckersley-Maslin; Tajda Klobučar; João von Gilsa Lopes; Felix Krueger; Annalisa Mupo; Ana Cláudia Raposo; David Oxley; Samantha Mancino; Anne-Valerie Gendrel; Bruno Bernardes de Jesus; Simão Teixeira da Rocha
Journal:  Nat Commun       Date:  2022-09-16       Impact factor: 17.694

6.  An Analysis of Phenotype and Genotype in a Large Cohort of Chinese Children with Angelman Syndrome.

Authors:  Xiaonan Du; Ji Wang; Shuang Li; Yu Ma; Tianqi Wang; Bingbing Wu; Yuanfeng Zhou; Lifei Yu; Yi Wang
Journal:  Genes (Basel)       Date:  2022-08-14       Impact factor: 4.141

Review 7.  Brain Long Noncoding RNAs: Multitask Regulators of Neuronal Differentiation and Function.

Authors:  Sarva Keihani; Verena Kluever; Eugenio F Fornasiero
Journal:  Molecules       Date:  2021-06-28       Impact factor: 4.411

Review 8.  Genotype-Phenotype Correlations in Angelman Syndrome.

Authors:  Lili Yang; Xiaoli Shu; Shujiong Mao; Yi Wang; Xiaonan Du; Chaochun Zou
Journal:  Genes (Basel)       Date:  2021-06-28       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.